Trump’s Plasma Push Stands to Delay Clearer Reading on Science
- With use widespread, patients could balk at taking a placebo
- Enrollment problems haunt studies of a long-heralded therapy
This article is for subscribers only.
The Trump administration’s decision to authorize the use of a blood-plasma treatment for Covid-19 with no clear evidence it works could frustrate efforts to better understand the therapy’s benefits.
Several clinical trials are examining the use of so-called convalescent plasma for Covid-19, but none have been completed and results aren’t expected for at least several more weeks.